Related Experiment Video
Updated: Nov 9, 2025
06:38
Induction of Ocular Surface Inflammation and Collection of Involved Tissues
Published on: August 4, 2022
2.5K
Association of Dupilumab with Intraocular Inflammation
Sneha Padidam1, Veena Raiji2, Ramana Moorthy3
1Retina Group of Washington, Chevy Chase, MD, USA.
Ocular Immunology and Inflammation
|April 7, 2021
Summary
Dupilumab, a treatment for atopic dermatitis, was associated with new-onset uveitis in four patients. These cases highlight potential intraocular inflammation risks with dupilumab therapy.
Area of Science:
- Ophthalmology
- Dermatology
- Immunology
Background:
- Atopic dermatitis is a chronic inflammatory skin condition.
- Dupilumab is a biologic therapy targeting interleukin-4 and interleukin-13 signaling pathways.
- Understanding the safety profile of dupilumab is crucial for patient management.
Purpose of the Study:
- To report four cases of intraocular inflammation, specifically uveitis, occurring after dupilumab treatment for atopic dermatitis.
- To investigate potential associations between dupilumab therapy and ocular inflammatory events.
Main Methods:
- Retrospective case series design.
- Inclusion of four patients who developed ocular inflammation during dupilumab treatment.
- Review of clinical data and ophthalmological findings.
Main Results:
- Four patients developed various forms of uveitis, including posterior scleritis, anterior/intermediate uveitis with cystoid macular edema, and placoid chorioretinitis.
- One patient experienced recurrence of intraocular inflammation upon re-initiation of dupilumab.
- Ocular inflammation manifested at different time points during dupilumab therapy.
Conclusions:
- Dupilumab treatment for atopic dermatitis may be associated with the development of intraocular inflammatory conditions.
- Ophthalmologists and dermatologists should be aware of these potential adverse effects.
- Further research is warranted to elucidate the mechanisms and incidence of these events.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
279
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
279
01:27Open Angle Glaucoma: Treatment
801
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
801
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
304
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
304
01:29Inflammatory Bowel Disease IV: Pharmacological Management
274
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
274
01:25Glaucoma: Overview
1.0K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.0K
01:28Angle Closure Glaucoma: Treatment
926
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
926